Biocryst Pharmaceuticals Inc. logo

BCRX

Biocryst Pharmaceuticals Inc.

$14.21

Earnings Summary

Revenue
$49.92Mn
Net Profits
$-74.2Mn
Net Profit Margins
-148.62%

Highlights

Revenue:

Biocryst Pharmaceuticals Inc.’s revenue jumped 161.94% since last year same period to $49.92Mn in the Q1 2022. On a quarterly growth basis, Biocryst Pharmaceuticals Inc. has generated 5.86% jump in its revenue since last 3-months.

Net Profits:

Biocryst Pharmaceuticals Inc.’s net profit fell -15.42% since last year same period to $-74.2Mn in the Q1 2022. On a quarterly growth basis, Biocryst Pharmaceuticals Inc. has generated -317.32% fall in its net profits since last 3-months.

Net Profit Margins:

Biocryst Pharmaceuticals Inc.’s net profit margin jumped 55.94% since last year same period to -148.62% in the Q1 2022. On a quarterly growth basis, Biocryst Pharmaceuticals Inc. has generated -294.21% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Biocryst Pharmaceuticals Inc. post its latest quarter earnings

EPS Estimate Current Quarter
-0.34
EPS Estimate Current Year
-0.34

Highlights

EPS Estimate Current Quarter:

Biocryst Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.34 - a 8.11% jump from last quarter’s estimates.

EPS Estimate Current Year:

Biocryst Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current year stand at -0.34.

Key Ratios

Key ratios of the Biocryst Pharmaceuticals Inc. post its Q1 2022 earnings

Earning Per Share (EPS)
-0.4
Return on Assets (ROA)
-0.29
Return on Equity (ROE)
-19.25
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Biocryst Pharmaceuticals Inc.’s earning per share (EPS) fell -11.11% since last year same period to -0.4 in the Q1 2022. This indicates that the Biocryst Pharmaceuticals Inc. has generated -11.11% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Biocryst Pharmaceuticals Inc.’s return on assets (ROA) stands at -0.29.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Biocryst Pharmaceuticals Inc.’s return on equity (ROE) stands at -19.25.

Dividend Per Share (DPS):

Biocryst Pharmaceuticals Inc. declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.37
-0.4
-8.11%

Company Information

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing.

Organisation
Biocryst Pharmaceuticals Inc.
Headquarters
Durham, North Carolina, US
Employees
246
Industry
Health Technology
CEO
Jon Stonehouse